Endocyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Endocyte and buy or sell other stocks, ETFs, and their options commission-free!

About ECYT

Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. 

CEO
Michael A. Sherman, MBA
CEOMichael A. Sherman, MBA
Employees
Employees
Headquarters
West Lafayette, Indiana
HeadquartersWest Lafayette, Indiana
Founded
1995
Founded1995
Employees
Employees

ECYT Key Statistics

Market cap
1.95B
Market cap1.95B
Price-Earnings ratio
-35.02
Price-Earnings ratio-35.02
Dividend yield
Dividend yield
Average volume
1.68M
Average volume1.68M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$24.00
52 Week high$24.00
52 Week low
$2.81
52 Week low$2.81

Stock Snapshot

The current Endocyte(ECYT) stock price is $24.00, with a market capitalization of 1.95B. The stock trades at a price-to-earnings (P/E) ratio of -35.02.

On 2026-04-03, Endocyte(ECYT) stock opened at —, reached a high of —, and a low of —.

Endocyte(ECYT) shares are trading with a volume of 0, against a daily average of 1.68M.

In the last year, Endocyte(ECYT) shares hit a 52-week high of $24.00 and a 52-week low of $2.81.

In the last year, Endocyte(ECYT) shares hit a 52-week high of $24.00 and a 52-week low of $2.81.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.